Who founded Adial Pharmaceuticals?

Adial Pharmaceuticals was founded by Bankole A. Johnson in 2017.

How much funding has Adial Pharmaceuticals raised?

Adial Pharmaceuticals has disclosed $31.6M raised across 17 rounds.

Where is Adial Pharmaceuticals headquartered?

Adial Pharmaceuticals is headquartered in Glen Allen, US.

Adial Pharmaceuticals

NASDAQ: ADIL

Glen Allen, US · Founded 2017 · Delaware corporation

Find your way into Adial Pharmaceuticals

Paths you didn't know you had: your email and LinkedIn already hold routes to the Adial Pharmaceuticals team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Adial Pharmaceuticals is a biopharmaceutical company developing treatments for addiction and inflammatory disease, including AT177, a colon-targeted AhR agonist for ulcerative colitis, and AD04, a genetically targeted serotonin-3 receptor antagonist in Phase 3 trials for Alcohol Use Disorder. It is publicly listed on Nasdaq under the ticker ADIL.

Biotech Healthtech Medical Devices

Founders & leadership

Adial Pharmaceuticals was founded in 2017 by Bankole A. Johnson.

Bankole A. Johnson Founder & CMO, AdialBankole A. Johnson is a physician and neuroscientist with a medical degree from the University of Glasgow and postgraduate training in psychiatry at UK institutions including Royal London Hospital and the Institute of Psychiatry, University of London. He holds a D.Sc. in Medicine from the University of Glasgow and has held academic and clinical leadership roles in neuroscience and psychiatry while conducting research in addiction neuroscience and neuropsychopharmacology.

Vinay Shah Chief Financial OfficerHe holds an MBA in Finance and is a Chartered Accountant with experience in biotech finance, IPO and follow-on financing, investor relations, and strategic financial planning.

Cary J. Claiborne Chief Executive OfficerCary J. Claiborne is Chief Executive Officer of Adial Pharmaceuticals, a Nasdaq-listed biopharmaceutical company developing treatments for addiction and inflammatory disease. He has over 35 years of business experience in the pharmaceutical and biotech sectors, and serves on the boards of NeuroSense Therapeutics and LadRx Corporation.

Tony Goodman Chief Operating Officer2024–2026Tony Goodman is Chief Operating Officer of Adial Pharmaceuticals, a biopharmaceutical company developing treatments for addiction and inflammatory disease. He has led M&A strategy and executed multiple acquisition and divestiture transactions in pharmaceutical and life sciences contexts.

William B. Stilley, IIIExecutive

Joseph M. Truluck CFO2017–2024Joseph M. Truluck is an executive officer at Adial Pharmaceuticals, a biopharmaceutical company developing treatments for addiction and inflammatory disease. He has led capital raising efforts exceeding $55M and guided the company through an IPO.

Board

James W. Newman, Jr.Board director

James K. AndersonBoard director

Kevin Schuyler, CFABoard director

Robertson H. GillilandBoard director

Jack ReichBoard director

Reported raises · per SEC filings

Form D private placements

$31.6M disclosed across 17 rounds · 2017–2025

▶$4.3MraisedDec 2025 · 1 investors · Pharmaceuticals

Rule 506(b)